Paul Hastings advised Viking Therapeutics on the offering. Viking Therapeutics, Inc. (Nasdaq: VKTX) executed its underwritten offering of $632.5 million of shares of its common stock....
Viking Therapeutics’ $632.5 Million Common Stock Offering
Kyverna Therapeutics’ $319 Million Upsized IPO
Paul Hastings advised Kyverna Therapeutics in connection with the company’s upsized initial public offering. Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell...